Advertisement

Cancer Immunology, Immunotherapy

, Volume 68, Issue 2, pp 257–268 | Cite as

Hyperresponsiveness to interferon gamma exposure as a response mechanism to anti-PD-1 therapy in microsatellite instability colorectal cancer

  • Wenli Yuan
  • Deyao Deng
  • Hongchao Jiang
  • Changling Tu
  • Xueqin Shang
  • Hongchun He
  • Ruize Niu
  • Jian DongEmail author
Original Article
  • 178 Downloads

Abstract

Colorectal cancer (CRC) with high-level microsatellite instability (MSI-H) tends to be associated with a better response to programmed death receptor-1 (PD-1) blockade than does microsatellite stable CRC. However, emerging evidence makes the use of programmed death ligand-1 (PD-L1) as a biomarker problematic. Here, we sought to characterize the interactions between PD-L1 expression and the response to PD-1 blockade therapy in BALB/c mice with a subcutaneous tumor challenge. We further focused on interferon gamma (IFNγ)-induced PD-L1 expression in an in vitro setting to evaluate the responsiveness to IFNγ exposure and the specific signaling of PD-1 in HCT116 and SW480 cell lines. In this study, enhanced PD-L1 expression increased survival in CT26 cells, and PD-1 blockade increased the CTL profile and apoptotic cells in mice with CRC. Our in vitro findings showed that PD-L1 expression was significantly upregulated by a low-dose IFNγ treatment, and the MSI-H cell line might exhibit hyperresponsiveness to IFNγ exposure partly through the JAK–STAT pathway. These results suggest that intrinsic PD-L1 in cooperation with extrinsic IFNγ exposure in CRC may be more responsive to anti-PD-1 therapy, mainly through the CTL profile in the tumor microenvironment.

Keywords

Colorectal cancer Microsatellite instability IFNγ PD-L1 CTL 

Abbreviations

CRC

Colorectal cancer

CTL

Cytotoxic T lymphocyte

DAPI

4′,6-Diamidino-2-phenylindole

EGFR

Epidermal growth factor receptor

FCM

Flow cytometry

HE

Hematoxylin and eosin

IFNγ

Interferon gamma

JAK/STAT3

Janus kinase/signal transducer and activator of transcription 3

MAPK

Mitogen-activated protein kinase

MSI-H

High-level microsatellite instability

MSS

Microsatellite stable

PD-1

Programmed death-1

PD-L1

Programmed death ligand-1

PI3K/AKT

Phosphatidylinositol 3 kinase/protein kinase B

PTEN

Phosphatase and tensin homology deleted on chromosome 10

RT-PCR

Reverse-transcription quantitative polymerase chain reactions

TUNEL

TdT-mediated dUTP nick-end labeling

Notes

Acknowledgements

We would like to thank Xiaojin Li (Central laboratory, the second hospital of Yunnan Province) for his technical assistance in flow cytometry.

Author contributions

Conceived and designed the experiments: WY and JD. Performed the experiments: WY, CT, XS, HJ and HH. Analyzed the data: WY and JD. Contributed reagents/animals: DD, HJ and RN. Wrote the paper: WY and JD.

Funding

This study was partially supported by the Association Foundation Program of Yunnan Provincial Science and Technology Department and Kunming Medical University (Grant number: 2017FE468(-228)), by the Foundation of Yunnan Medical Science and Technology (Grant number: 2016NS124), and by the National Natural Science Foundation of China (Grant number: 81660472).

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest.

Ethical approval and ethical standards

The animal study was approved by the Animal Experimental Ethical Committee of Kunming Medical University (date of approval: June 2017). The experimental mice used in this study were obtained from the Laboratory Animal Center of Kunming Medical University. All experimental procedures were conducted according to the protocols approved by the National Institute of Health’s Guidelines for the Care and Use of Laboratory Animals. This article does not contain any studies with human participants performed by any of the authors.

Cell line authentication

Human CRC cell lines HCT116 and SW480 were obtained from the Institute of Zoology, Chinese Academy of Sciences (Kunming, China), and rat CRC CT26 cells were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cell Bank, Type Culture Collection, Chinese Academy of Sciences (CBTCCCAS) can provide the Certificate of STR Analysis.

Supplementary material

262_2018_2270_MOESM1_ESM.pdf (264 kb)
Supplementary material 1 (PDF 263 KB)

References

  1. 1.
    Westdorp H, Fennemann FL, Weren RD et al (2016) Opportunities for immunotherapy in microsatellite instable colorectal cancer. Cancer Immunol Immunother 65:1249–1259CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Bupathi M, Wu C (2016) Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others. J Gastrointest Oncol 7:713–720CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Marisa L, Svrcek M, Collura A et al (2018) The balance between cytotoxic T-cell lymphocytes and immune checkpoint expression in the prognosis of colon tumors. J Natl Cancer Inst.  https://doi.org/10.1093/jnci/djx136 Google Scholar
  4. 4.
    Miguchi M, Hinoi T, Shimomura M et al (2016) Gasdermin C is upregulated by inactivation of transforming growth factor β receptor type II in the presence of mutated Apc, promoting colorectal cancer proliferation. PLoS One 11:e0166422CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Ogawa M, Watanabe M, Hasegawa T et al (2017) Expression of CXCR-4 and IDO in human colorectal cancer: an immunohistochemical approach. Mol Clin Oncol 6:701–704CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Johdi NA, Ait-Tahar K, Sagap I et al (2017) Molecular signatures of human regulatory T cells in colorectal cancer and polyps. Front Immunol 8:620CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Kim ST, Klempner SJ, Park SH et al (2017) Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. Oncotarget 8:77415–77423PubMedCentralGoogle Scholar
  8. 8.
    Javed A, Arguello D, Johnston C et al (2017) PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. Immunotherapy 9:1323–1330CrossRefGoogle Scholar
  9. 9.
    Oya Y, Yoshida T, Kuroda H et al (2017) Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer. Oncotarget 8:103117–103128CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Bedke J, Stühler V, Stenzl A et al (2018) Immunotherapy for kidney cancer: status quo and the future. Curr Opin Urol 28:8–14Google Scholar
  11. 11.
    Lee KS, Kwak Y, Ahn S et al (2017) Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer. Cancer Immunol Immunother 66:927–939CrossRefGoogle Scholar
  12. 12.
    Toh JWT, de Souza P, Lim SH et al (2016) The potential value of immunotherapy in colorectal cancers: review of the evidence for programmed death-1 inhibitor therapy. Clin Colorectal Cancer 15:285–229CrossRefGoogle Scholar
  13. 13.
    Korehisa S, Oki E, Iimori M et al (2018) Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability. Int J Cancer 142:822–832CrossRefGoogle Scholar
  14. 14.
    Ritprajak P, Azuma M (2015) Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol 51:221–228CrossRefGoogle Scholar
  15. 15.
    Kursunel MA, Esendagli G (2016) The untold story of IFN-γ in cancer biology. Cytokine Growth Factor Rev 31:73–81CrossRefGoogle Scholar
  16. 16.
    Mimura K, Teh JL, Okayama H et al (2017) PD-L1 expression is mainly regulated by interferon gamma associated with JAK–STAT pathway in gastric cancer. Cancer Sci 109:43–53CrossRefPubMedCentralGoogle Scholar
  17. 17.
    Zhang X, Zeng Y, Qu Q et al (2017) PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer. Int J Clin Oncol 22:1026–1033CrossRefGoogle Scholar
  18. 18.
    Kuttke M, Sahin E, Pisoni J et al (2016) Myeloid PTEN deficiency impairs tumor-immune surveillance via immune-checkpoint inhibition. Oncoimmunology 5:e1164918CrossRefPubMedCentralGoogle Scholar
  19. 19.
    Dong ZY, Zhang JT, Liu SY et al (2017) EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. Oncoimmunology 6:e1356145CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Llosa NJ, Cruise M, Tam A et al (2015) The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 5:43–51CrossRefGoogle Scholar
  21. 21.
    Wang L, Liu Z, Fisher KW et al (2018) Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer. Hum Pathol 71:20–29CrossRefGoogle Scholar
  22. 22.
    Xu JX, Xiong W, Zeng Z et al (2017) Effect of ART1 on the proliferation and migration of mouse colon carcinoma CT26 cells in vivo. Mol Med Rep 15:1222–1228CrossRefPubMedCentralGoogle Scholar
  23. 23.
    Okita R, Maeda A, Shimizu K et al (2017) PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer. Cancer Immunol Immunother 66:865–876CrossRefGoogle Scholar
  24. 24.
    Tao LH, Zhou XR, Li FC et al (2017) A polymorphism in the promoter region of PD-L1 serves as a binding-site for SP1 and is associated with PD-L1 overexpression and increased occurrence of gastric cancer. Cancer Immunol Immunother 66:309–318CrossRefGoogle Scholar
  25. 25.
    Berzaghi R, Maia VS, Pereira FV et al (2017) SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression. Sci Rep 7:40585CrossRefPubMedCentralGoogle Scholar
  26. 26.
    Gao J, Shi LZ, Zhao H et al (2016) Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167:397–404CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Clinical LaboratoryThe Fourth Affiliated Hospital of Kunming Medical UniversityKunmingPeople’s Republic of China
  2. 2.The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer CenterKunmingPeople’s Republic of China
  3. 3.The Affiliated Children’s Hospital of Kunming Medical UniversityKunmingPeople’s Republic of China
  4. 4.Department of Cadre Medical Branch, Yunnan Cancer Hospital, Yunnan Cancer CenterThe Third Affiliated Hospital of Kunming Medical UniversityKunmingPeople’s Republic of China
  5. 5.Department of OncologyThe Fourth Affiliated Hospital of Kunming Medical UniversityKunmingPeople’s Republic of China
  6. 6.Department of General SurgeryThe Fourth Affiliated Hospital of Kunming Medical UniversityKunmingPeople’s Republic of China
  7. 7.Department of Laboratory ZoologyKunming Medical UniversityKunmingPeople’s Republic of China

Personalised recommendations